Literature DB >> 32135517

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

John A Thompson1, Bryan J Schneider2, Julie Brahmer3, Stephanie Andrews4, Philippe Armand5, Shailender Bhatia1, Lihua E Budde6, Luciano Costa7, Marianne Davies8, David Dunnington9, Marc S Ernstoff10, Matthew Frigault11, Benjamin H Kaffenberger12, Matthew Lunning13, Suzanne McGettigan14, Jordan McPherson15, Nisha A Mohindra16, Jarushka Naidoo3, Anthony J Olszanski17, Olalekan Oluwole18, Sandip P Patel19, Nathan Pennell20, Sunil Reddy21, Mabel Ryder22, Bianca Santomasso23, Scott Shofer24, Jeffrey A Sosman16, Yinghong Wang25, Ryan M Weight26, Alyse Johnson-Chilla27, Griselda Zuccarino-Catania27, Anita Engh27.   

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32135517     DOI： 10.6004/jnccn.2020.0012

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  79 in total

Review 1.  Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.

Authors:  Kathryn Lurain; Ramya Ramaswami; Robert Yarchoan; Thomas S Uldrick
Journal:  Curr HIV/AIDS Rep       Date:  2020-10       Impact factor: 5.071

2.  Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.

Authors:  Ranjan Pathak; Anjan Katel; Erminia Massarelli; Victoria M Villaflor; Virginia Sun; Ravi Salgia
Journal:  Oncologist       Date:  2021-08-25

Review 3.  Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review.

Authors:  Christopher Ma; John K MacDonald; Tran M Nguyen; Niels Vande Casteele; Bryan Linggi; Pavine Lefevre; Yinghong Wang; Brian G Feagan; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-03-26       Impact factor: 3.199

4.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Renal Toxicity.

Authors:  Maen Abdelrahim; Ala Abudayyeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Authors:  Jian-Qing Mi; Jie Xu; Jianfeng Zhou; Weili Zhao; Zhu Chen; J Joseph Melenhorst; Saijuan Chen
Journal:  Front Med       Date:  2021-12-18       Impact factor: 4.592

Review 7.  Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care.

Authors:  Alina Basnet; Asrar Alahmadi; Ajeet Gajra
Journal:  Curr Oncol Rep       Date:  2022-07-28       Impact factor: 5.945

8.  Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY.

Authors:  Anushree C Shirali
Journal:  Kidney360       Date:  2021-09-17

Review 9.  Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects.

Authors:  Wenlu Zou; Jie Lu; Yan Hao
Journal:  J Inflamm Res       Date:  2021-07-08

10.  Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series.

Authors:  Prabalini Rajendram; Heather Torbic; Abhijit Duggal; Jeannee Campbell; Michael Hovden; Vikram Dhawan; Stephen M Pastores; Cristina Gutierrez
Journal:  J Crit Care       Date:  2021-06-04       Impact factor: 4.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.